1. Home
  2. SENS vs BWAY Comparison

SENS vs BWAY Comparison

Compare SENS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$7.97

Market Cap

476.9M

Sector

Industrials

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$12.06

Market Cap

547.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SENS
BWAY
Founded
1996
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
476.9M
547.7M
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
SENS
BWAY
Price
$7.97
$12.06
Analyst Decision
Buy
Strong Buy
Analyst Count
8
3
Target Price
$13.67
★ $19.27
AVG Volume (30 Days)
★ 621.9K
107.7K
Earning Date
11-04-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $16,389,000.00
N/A
Revenue This Year
$82.21
$32.42
Revenue Next Year
$55.63
$23.40
P/E Ratio
★ N/A
$81.98
Revenue Growth
★ 19.85
N/A
52 Week Low
$4.79
$11.34
52 Week High
$10.64
$26.63

Technical Indicators

Market Signals
Indicator
SENS
BWAY
Relative Strength Index (RSI) 34.55 42.35
Support Level $7.35 $11.90
Resistance Level $8.49 $14.71
Average True Range (ATR) 0.47 0.45
MACD -0.27 0.02
Stochastic Oscillator 4.33 26.60

Price Performance

Historical Comparison
SENS
BWAY

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: